TG Therapeutics IncNASDAQ:TGTX
- LAST PRICE25.3600
- TODAY'S CHANGE (%)0.1100 (0.4356%)
- Bid / Lots25.3300/ 2
- Ask / Lots25.3700/ 2
- Open / Previous Close25.6000 / 25.2500
- Day Range
- 52 Week Range
- Volume1,094,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TGTX |
|---|---|---|
| 09:32 ET | 35231 | 25.78 |
| 09:34 ET | 34016 | 25.39 |
| 09:36 ET | 11365 | 25.37 |
| 09:38 ET | 19525 | 25.4 |
| 09:39 ET | 6654 | 25.4698 |
| 09:41 ET | 3050 | 25.335 |
| 09:43 ET | 34422 | 25.2 |
| 09:45 ET | 40629 | 25.2096 |
| 09:48 ET | 16469 | 25.36 |
| 09:50 ET | 15400 | 25.38 |
| 09:52 ET | 17763 | 25.43 |
| 09:54 ET | 10272 | 25.46 |
| 09:56 ET | 26272 | 25.54 |
| 09:57 ET | 30799 | 25.715 |
| 09:59 ET | 17854 | 25.91 |
| 10:01 ET | 68877 | 26.015 |
| 10:03 ET | 12572 | 25.88 |
| 10:06 ET | 4658 | 25.93 |
| 10:08 ET | 13087 | 25.95 |
| 10:10 ET | 19828 | 25.9 |
| 10:12 ET | 33437 | 25.965 |
| 10:14 ET | 64255 | 26 |
| 10:15 ET | 15059 | 25.93 |
| 10:17 ET | 4477 | 25.8259 |
| 10:19 ET | 10958 | 25.86 |
| 10:21 ET | 25671 | 25.945 |
| 10:24 ET | 15672 | 25.9 |
| 10:26 ET | 16534 | 25.8 |
| 10:28 ET | 23830 | 25.8082 |
| 10:30 ET | 8529 | 25.846 |
| 10:32 ET | 9518 | 25.905 |
| 10:33 ET | 10433 | 25.91 |
| 10:35 ET | 15113 | 25.87 |
| 10:37 ET | 6966 | 25.8 |
| 10:39 ET | 2214 | 25.84 |
| 10:42 ET | 19761 | 25.8165 |
| 10:44 ET | 19707 | 25.61 |
| 10:46 ET | 56553 | 25.49 |
| 10:48 ET | 26624 | 25.4975 |
| 10:50 ET | 19277 | 25.4846 |
| 10:51 ET | 13949 | 25.457989 |
| 10:53 ET | 8711 | 25.395 |
| 10:55 ET | 11088 | 25.37 |
| 10:57 ET | 10162 | 25.36 |
Yesterday
DJ TG Therapeutics Price Target Maintained With a $49.00/Share by HC Wainwright & Co., from 22 hours ago by Dow Jones
22 hours ago by Dow JonesNew BRIUMVI(R) (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis, from 7:15AM ET on Wednesday Sep 18, 2024 by Dow Jones
7:15AM ET on Wednesday Sep 18, 2024 by Dow JonesNew Data for BRIUMVI(R) (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment, from 7:00AM ET on Wednesday Sep 18, 2024 by Dow Jones
7:00AM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 6, 2024
Sep 5, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TG Therapeutics Inc | 3.9B | 42.3x | --- |
Axsome Therapeutics Inc | 4.4B | -14.4x | --- |
ADMA Biologics Inc | 4.5B | 136.0x | --- |
Denali Therapeutics Inc | 4.4B | -11.0x | --- |
Twist Bioscience Corp | 2.8B | -12.8x | --- |
CRISPR Therapeutics AG | 4.2B | -15.7x | --- |
Company Information
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Contact Information
- Headquarters
- 3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435
- Phone
- 212-554-4484
- Fax
- 212-554-4531
Executives
- Chairman of the Board, President, Chief Executive Officer
- Michael Weiss
- Chief Financial Officer, Treasurer, Corporate Secretary
- Sean Power
- Lead Independent Director
- Laurence Charney
- Independent Director
- Yann Echelard
- Independent Director
- Kenneth Hoberman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9B |
|---|---|
Revenue (TTM) | $346.7M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.21 |
EPS | $0.60 |
Book Value | $1.06 |
P/E Ratio | 42.3x |
Price/Sales (TTM) | 11.3 |
Price/Cash Flow (TTM) | 40.8x |
Operating Margin | 29.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
